Overview
Designing antibodies, proteins, and drug molecules through molecular structure prediction and generative AI
Funding
Amounts as reported; USD estimates shown only when they matchListed 3 funding records. Latest funding: $400M (Series C), Jul 14, 2026.
| Date | Amount | Investors | Sources |
|---|---|---|---|
| Jul 14, 2026 | $400M · Series C | Index Ventures | 1 source Source ↗ |
Evidence Chai Discovery Raises $400M Series C at ~$3.8B ValuationOn July 14, 2026, per Chai Discovery, generative protein and antibody design company raised $400M in a Series C backed by Index Ventures at a valuation of about $3.8B. The company was co-founded by Joshua Meier, Jack Dent, Matthew McPartlon and Jacques Boitreaud. Translated source brief, not a quotation. Check the original before citing. Sources · 1
| |||
| Aug 7, 2025 | $70M · Series A | DST Global, Menlo Ventures, OpenAI, Thrive Capital, Yosemite | 1 source Source ↗ |
Evidence No source brief is attached to this record. Sources · 1
DST Global, Menlo Ventures, OpenAI, Thrive Capital, Yosemite | |||
| Sep 11, 2024 | $30M · Seed | OpenAI, Thrive Capital | No source link |
Evidence No source brief is attached to this record. Sources · 0
| |||
Select ▸ on a row to see its source brief and links.
Valuation
Amounts as reported; USD estimates shown only when they matchListed 3 valuation records. Latest valuation: ~$3.8B (Series C), Jul 14, 2026.
2 listed records lack a clear date or positive USD estimate for the chart.
| Date | Amount | Investors | Sources |
|---|---|---|---|
| Jul 14, 2026 | ~$3.8B · Series C | Index Ventures | 1 source Source ↗ |
Evidence Chai Discovery Raises $400M Series C at ~$3.8B ValuationOn July 14, 2026, per Chai Discovery, generative protein and antibody design company raised $400M in a Series C backed by Index Ventures at a valuation of about $3.8B. The company was co-founded by Joshua Meier, Jack Dent, Matthew McPartlon and Jacques Boitreaud. Translated source brief, not a quotation. Check the original before citing. Sources · 1
| |||
| Aug 7, 2025 | — · Series A | DST Global, Menlo Ventures, OpenAI, Thrive Capital, Yosemite | 1 source Source ↗ |
Evidence No source brief is attached to this record. Sources · 1
DST Global, Menlo Ventures, OpenAI, Thrive Capital, Yosemite | |||
| Sep 11, 2024 | — · Seed | OpenAI, Thrive Capital | No source link |
Evidence No source brief is attached to this record. Sources · 0
| |||
Select ▸ on a row to see its source brief and links.
Revenue
Amounts as reported; USD estimates shown only when they matchNo revenue records are listed yet.
No revenue rows to list.
Team, products & investors
Sources · 0Sources & provenance
English text is maintained separately from the original record. Consult the original source before citing a fact.
No source links are available for this profile.
Original source text
Names may use phonetic renderings when no English name is supplied. The original wording is retained below.
以分子结构预测和生成式 AI 设计抗体、蛋白及药物分子